Nasopharyngitis

Newron Pharmaceuticals announced positive topline results from its phase 2/3 study of evenamide for patients with chronic schizophrenia who have an inadequate response to current treatment with a second-generation antipsychotic.

Treatment with apraglutide resulted in a 52% reduction in weekly parenteral support volume at 1 year among nine patients with short bowel syndrome with intestinal failure and colon-in-continuity, according to data presented at UEG week.